Background: The world is now challenging the pandemic of COVID-19 infection. This is the third and most extensive pandemic. Previous studies showed the plausibility of vitamin D prophylaxis and therapy for COVID-19, particularly in settings where hypovitaminosis D is frequent. Recent study from Indonesian showed that the prevalence of vitamin D deficiency was 23.0%. The examination of vitamin D status is not a routine in the Indonesian clinical setting. Methods: This study is a case series from confirmed cases of COVID-19 in Bethesda Hospital Yogyakarta Indonesia. The data of clinical symptoms, signs and laboratory examinations were obtained from the electronic medical records. The vitamin D status was measured by Enzyme-Linked Fluorescent Assay (ELFA) method. We searched PubMed and Google Scholar for studies that included terms for Vitamin D and COVID-19. Results: The data were obtained from 10 participants consisting of 50% male and 50% female. The mean age was 49.6 years. The prevalence of vitamin D deficiency in this study was 90% (vitamin D levels < 20 ng/mL) and 10% of insufficiency (vitamin D levels < 30 ng/mL). Patients in this study had various symptoms such as fatigue (60%), fever (50%), dry cough (40%), non-specific headache (10%), and diarrhea (10%); have no symptoms (20%); and also had the various chronic diseases as comorbidity such as hypertension (40%), diabetes (10%), COPD (10%), and post stroke (10%). Conclusions: All of the COVID-19 patients in this study had hypovitaminosis D. The prevalence of vitamin D deficiency in this case series is 90% and only 1 patient (10%) had vitamin D insufficiency. There are many health benefits of vitamin D and very few adverse effects. Randomized controlled trials need to determine and evaluate this recommendation in preventing or treating COVID-19. Clinicians should continue to treat people with vitamin D deficiency especially in managing COVID-19 patients.
Background The world is now challenging the pandemic of COVID-19 infection. Previous studies showed the plausibility of Vitamin D prophylaxis and therapy for COVID-19, particularly in settings where hypovitaminosis D is frequent. Recent study from Indonesian showed that prevalence of vitamin D deficiency were 23.0%. The examination of Vitamin D status is not a routine in Indonesian clinical setting. Methods This study is a Case Series from confirmed cases of COVID-19 in Bethesda hospital Yogyakarta Indonesia. The data of clinical symptoms, clinical signs, and laboratory examination were obtained from electronic medical record. The vitamin D status was measured by standardized laboratory method. We searched PubMed and Google Scholar for studies that included terms for Vitamin D and COVID-19. Results The data was obtained from 10 participants consist of 50% male and 50% female. The mean of age was 49.6 years. The prevalence of vitamin D deficiency in this case was 90% and 10% of insufficiency. Patients in this case had various symptom and also had various chronic disease as comorbidity. Conclusions The prevalence of vitamin D deficiency in this case series in Bethesda hospital Yogyakarta, Indonesia is 90% and 10% vitamin D insufficiency. We found no clinical evidence that vitamin D supplements are beneficial in preventing or treating COVID-19. Randomized controlled trials need to determine and evaluated this recommendation.
Apheresis for platelet concentrates has been used more frequently in recent years due to the rising demand for platelet transfusions for patients with various medical and surgical disorders. Studies on the effect of repeated or frequent plateletpheresis on the donor's hematological parameters are still limited. This article will review the effects of plateletpheresis on the donor's hematological parameters to define the proper deferral for repeat donation because this treatment is relatively new and requires early repeat donations. We systematically search the studies and review current evidence about the effects of plateletpheresis on blood parameters in healthy donors. Literature tracking was performed on PubMed, CENTRAL, EbscoHost, and ProQuest databases. There are different effects, and some studies reveal that plateletpheresis can decrease hematological parameters (HB, HCT, PLT, PDW). Some can cause an increase in hematological parameters (HB, HCT). These different effects can be caused by variable cell separator technologies, residual blood volume lost during apheresis, and mechanical hemolysis of blood in tubes by machine pumps
25 October 2022 in World Journal of Current Medical and Pharmaceutical Research
Apheresis for platelet concentrates has been used more frequently in recent years due to the rising demand for platelet transfusions for patients with various medical and surgical disorders. Studies on the effect of repeated or frequent plateletpheresis on the donor's hematological parameters are still limited. This article will review the effects of plateletpheresis on the donor's hematological parameters to define the proper deferral for repeat donation because this treatment is relatively new and requires early repeat donations. We systematically search the studies and review current evidence about the effects of plateletpheresis on blood parameters in healthy donors. Literature tracking was performed on PubMed, CENTRAL, EbscoHost, and ProQuest databases. There are different effects, and some studies reveal that plateletpheresis can decrease hematological parameters (HB, HCT, PLT, PDW). Some can cause an increase in hematological parameters (HB, HCT). These different effects can be caused by variable cell separator technologies, residual blood volume lost during apheresis, and mechanical hemolysis of blood in tubes by machine pumps.